Growth Metrics

Ironwood Pharmaceuticals (IRWD) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $40.1 million.

  • Ironwood Pharmaceuticals' Income towards Parent Company rose 99928.69% to $40.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $130.5 million, marking a year-over-year increase of 15681.0%. This contributed to the annual value of $102.8 million for FY2024, which is 10816.89% up from last year.
  • Ironwood Pharmaceuticals' Income towards Parent Company amounted to $40.1 million in Q3 2025, which was up 99928.69% from $23.6 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Income towards Parent Company high stood at $391.3 million for Q2 2021, and its period low was -$1.1 billion during Q2 2023.
  • In the last 5 years, Ironwood Pharmaceuticals' Income towards Parent Company had a median value of $38.8 million in 2022 and averaged -$22.4 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Income towards Parent Company crashed by 303830.1% in 2023 and then skyrocketed by 284406.98% in 2025.
  • Ironwood Pharmaceuticals' Income towards Parent Company (Quarter) stood at $41.4 million in 2021, then increased by 18.16% to $48.9 million in 2022, then tumbled by 567.15% to -$228.3 million in 2023, then soared by 145.63% to $104.2 million in 2024, then crashed by 61.52% to $40.1 million in 2025.
  • Its Income towards Parent Company stands at $40.1 million for Q3 2025, versus $23.6 million for Q2 2025 and -$37.4 million for Q1 2025.